Please typ	e a plus sign (+)	inside this box	→	+
------------	-------------------	-----------------	---	---

Substitute for form 1449A/PTO

PTO/SB/08A (09-00
Approved for use through 10/31/2002. OMB 665 705
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMITTEE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

MAR O 6 2002

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

C	Complete if Known
Application Number	09/934,631
Filing Date	08/22/2001
First Named Inventor	Frank HIMMELSBACH
Group Art Unit	1624
Examiner Name	
Attorney Docket Number	5/1303

				U.S. PATENT DOCU	JMENTS		
Examiner	xaminer Cite		t Document Kind Code <sup>2</sup>	Name of Patentee or Applicant	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant	
nitials*	No.1	Number	(if known)	of Cited Document	MM-DD-YYYY	Figures Appear	
				•			
					+		
			<del></del>				
				<del> </del>			

				FOR	EIGN PATENT DOCUMENT	'S		
Examiner Initials*	Cite No.1	Office	Foreign Patent Doo 3 Number <sup>4</sup>	cument Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т6
H.L.		EP	0 787 722	A1	American Cyanamid Co.	08/06/1997		
i		wo	00 18740	A1	American Cyanamid Co.	04/06/2000		\coprod.
		wo	00 55141	A1	BI Pharma KG	09/21/2000	-	
		wo	96 33980	A1	Zeneca Limited	10/31/1996		
		wo	97 30035	A1	Zeneca Limited	08/21/1997		Д.
		WÖ	97 32856	A1	Zeneca Limited	09/12/1997		
1			98 13354	A1	Zeneca Limited	04/02/1998		
11.6			99 09016	A1	American Cyanamid Co.	02/25/1999		+
		<del>                                     </del>						+-

Examiner		Date	-11.
	Hong Kin	Considered	S//37/03
Signature	man per	Considered	17117

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>8</sup> Applicant is to place a check mark here if English language Translation is attached.

	e for form 1449B/			spond to a collection of information	mplete if Known	~
				Application Number	09/934,631	Ra
INFO	DRMATIC	ON DIS	CLOSURE	Filing Date	08/22/2001	1/4/
			PPLICANT	First Named Inventor	Frank HIMMELSBAX	H
SIA	I MINIMI	רום	LIOAN	Group Art Unit	1624	5N2
	(use as mar	y sheets as	s necessary)	Examiner Name		1/5/
Sheet	2	of	2	Attorney Docket Number	5/1303	

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS					
OIPE	Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
0 . 2002	<u></u> <u><u></u><u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u> </u></u>		BOSCHELLI; "Small molecule inhibitors of receptor tyrosine kinases"; Review Article - Chemical Sciences				
MAR U 6 2002	<del>y</del>				ŀ		
•					Ī		
		-					
•					]		
		-		_	-		

Examiner Signature Onsidered S/15/03

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.